Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 9/20 | 0.57 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.56 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | NADK | O95544 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL788626 | 1.00 | AHCY (0.57) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL674401 | 1.00 | AHCY (0.57) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL9777803 | 0.88 | AHCY (0.55) | AHCYPRMT5WDR77ADORA1NADK | |
| SCHEMBL24478703 | 0.84 | PRMT5 (0.73) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL22326785 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL21413837 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL800346 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL22326787 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL18520788 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A | |
| SCHEMBL13173634 | 0.80 | PRMT5 (0.64) | AHCYPRMT5WDR77ADORA1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058669-A1 | PROCESS FOR THE TREATMENT OF ORGANOPHOSPHATE POISONING | NEDERLANDSE ORGANISATIE VOR TOEGEPASTNATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2002-05-16 | — | — | US | claimed |
| EP-0755254-B1 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED INJURY USING ADENOSINE AND PURINO RECEPTOR ANTAGONISTS | UNIV PENNSYLVANIA (US) | 2005-05-18 | — | — | EP | disclosed |
| US-20020058669-A1 | PROCESS FOR THE TREATMENT OF ORGANOPHOSPHATE POISONING | NEDERLANDSE ORGANISATIE VOR TOEGEPASTNATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2002-05-16 | — | — | US | disclosed |
| EP-0755254-A4 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED INJURY USING ADENOSINE AND PURINO RECEPTOR ANTAGONISTS | UNIV PENNSYLVANIA (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-1087776-A1 | A PROCESS FOR THE TREATMENT OF ORGANOPHOSPHATE POISONING | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2001-04-04 | — | — | EP | disclosed |
| EP-1044003-A4 | COMPOSITIONS AND METHODS FOR USE IN ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED TISSUE INJURY | UNIV PENNSYLVANIA (US) | 2000-12-27 | — | — | EP | disclosed |
| EP-1044003-A1 | COMPOSITIONS AND METHODS FOR USE IN ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED TISSUE INJURY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1999065501-A1 | A PROCESS FOR THE TREATMENT OF ORGANOPHOSPHATE POISONING | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999034803-A1 | COMPOSITIONS AND METHODS FOR USE IN ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED TISSUE INJURY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1999-07-15 | — | — | WO | disclosed |
| EP-0383759-B1 | N6 SUBSTITUTED 9-METHYLADENINES: A NEW CLASS OF ADENOSINE RECEPTOR ANTAGONISTS | DISCOVERY THERAPEUTICS INC (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0755254-A1 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED INJURY USING ADENOSINE AND PURINO RECEPTOR ANTAGONISTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995026728-A1 | PREVENTION AND TREATMENT OF ISCHEMIA-REPERFUSION AND ENDOTOXIN-RELATED INJURY USING ADENOSINE AND PURINO RECEPTOR ANTAGONISTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1995-10-12 | — | — | WO | disclosed |
| WO-1995011681-A1 | HUMAN ADENOSINE RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| WO-1994023723-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE PROMOTION OF WOUND HEALING | NEW YORK UNIVERSITY (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058669-A1 | PROCESS FOR THE TREATMENT OF ORGANOPHOSPHATE POISONING | ADORA3, ADORA1, ADORA2A | AHCY 369/4885PRMT5 2315/4885WDR77 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.